Cirrhosis
Conditions
Interventions
Case group:None
Sponsors
The Second Hospital of Nanjing
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age: at least 18 years old. 2. Diagnosis: Cirrhosis is clearly diagnosed by clinical, biochemical, imaging (ultrasound, CT, MRI or transient elastography) and/or histopathology. 3. Etiology includes but is not limited to: viral hepatitis (B, C), alcoholic, non-alcoholic steatohepatitis (NASH/MAFLD), autoimmune liver disease (autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis), inherited metabolic liver disease. 4. Disease stage: patients in any of the following disease stages: (1) Compensated cirrhosis: no previous history of severe complications such as ascites, gastrointestinal bleeding, or hepatic encephalopathy. (2) Non-acute decompensated cirrhosis: previous decompensated events (e.g., ascites, bleeding), but stable for >= 3 months at enrolment. For example, stable regression of ascites on diuretic therapy, no recurrence of bleeding after previous bleeding by endoscopic or pharmacological secondary prevention. (3) Acute decompensated cirrhosis: patients admitted on this occasion due to new or worsening cirrhotic complications (e.g. ascites, spontaneous bacterial peritonitis, hepatic encephalopathy, ruptured oesophagogastric fundal variceal haemorrhage, etc.). 5. Informed consent: patients or their legal representatives are able to understand and voluntarily sign a written informed consent form (for the prospective cohort part). For the retrospective cohort, a waiver of informed consent will be requested from the Ethics Committee.
Exclusion criteria
Exclusion criteria: 1. PSVD: patients with portal hypertension caused by non-cirrhotic factors (e.g. Buga syndrome, schistosomiasis, congenital liver fibrosis, cardiogenic cirrhosis, etc.). 2. Combined with other serious organ diseases: 3. suffering from severe cardiac, pulmonary and renal insufficiency (not liver disease related) with a life expectancy of 32) and first diagnosis. 7. Special groups: pregnant or lactating women. 8. Inability to cooperate with follow-up: severe mental or cognitive impairment, unable to cooperate with the completion of questionnaires, examinations and regular follow-up. 9. Inadequate data quality: For the retrospective cohort component, core baseline data or outcome data were severely missing (>40%) and could not be used for analysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pH-related adverse events;Hepatic mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Readmission rate; | — |
Countries
China
Contacts
Public ContactYongfeng Yang
The Second Hospital of Nanjing
Outcome results
None listed